<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               14 CLINICAL STUDIES<BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.1 Updated Adjuvant Treatment of Early Breast Cancer <BR>                     <BR>                        In a multicenter study enrolling over 8,000 postmenopausal women with resected, receptor-positive early breast cancer, one of the following treatments was randomized in a double-blind manner: <BR>                        <BR>                           <BR>                               Option 1: <BR>                           <BR>                               A. tamoxifen for 5 years <BR>                           <BR>                               B. letrozole for 5 years <BR>                           <BR>                               C. tamoxifen for 2 years followed by letrozole for 3 years <BR>                           <BR>                               D. letrozole for 2 years followed by tamoxifen for 3 years <BR>                           <BR>                               Option 2: <BR>                           <BR>                               A. tamoxifen for 5 years <BR>                           <BR>                               B. letrozole for 5 years <BR>                        <BR>                        The study in the adjuvant setting, BIG 1-98 was designed to answer two primary questions: whether letrozole for 5 years was superior to tamoxifen for 5 years (Primary Core Analysis) and whether switching endocrine treatments at 2 years was superior to continuing the same agent for a total of 5 years (Sequential Treatments Analysis). Selected baseline characteristics for the study population are shown in Table 5. The primary endpoint of this trial was disease-free survival (DFS) (i.e., interval between randomization and earliest occurrence of a local, regional, or distant recurrence, or invasive contralateral breast cancer, or death from any cause). The secondary endpoints were overall survival (OS), systemic disease-free survival (SDFS), invasive contralateral breast cancer, time to breast cancer recurrence (TBR) and time to distant metastasis (TDM). <BR>                        The Primary Core Analysis (PCA) included all patients and all follow-up in the monotherapy arms in both randomization options, but follow-up in the two sequential treatments arms was truncated 30 days after switching treatments. The PCA was conducted at a median treatment duration of 24 months and a median follow-up of 26 months. Letrozole was superior to tamoxifen in all endpoints except overall survival and contralateral breast cancer [e.g., DFS: hazard ratio, HR 0.79; 95% CI (0.68, 0.92); P = 0.002; SDFS: HR 0.83; 95% CI (0.70, 0.97); TDM: HR 0.73; 95% CI (0.60, 0.88); OS: HR 0.86; 95% CI (0.70, 1.06). <BR>                        In 2005, based on recommendations by the independent Data Monitoring Committee, the tamoxifen arms were unblinded and patients were allowed to complete initial adjuvant therapy with letrozole (if they had received tamoxifen for at least 2 years) or to start extended adjuvant treatment with letrozole (if they had received tamoxifen for at least 4.5 years) if they remained alive and disease-free. In total, 632 patients crossed to letrozole or another aromatase inhibitor. Approximately 70% (448) of these 632 patients crossed to letrozole to complete initial adjuvant therapy and most of these crossed in years 3 to 4. All of these patients were in Option 1. A total of 184 patients started extended adjuvant therapy with letrozole (172 patients) or with another aromatase inhibitor (12 patients). To explore the impact of this selective crossover, results from analyses censoring follow-up at the date of the selective crossover (in the tamoxifen arm) are presented for the Monotherapy Arms Analysis (MAA). <BR>                        The PCA allowed the results of letrozole for 5 years compared with tamoxifen for 5 years to be reported in 2005 after a median follow-up of only 26 months. The design of the PCA is not optimal to evaluate the effect of letrozole after a longer time (because follow-up was truncated in two arms at around 25 months). The Monotherapy Arms Analysis (ignoring the two sequential treatment arms) provided follow-up equally as long in each treatment and did not over-emphasize early recurrences as the PCA did. The MAA thus provides the clinically appropriate updated efficacy results in answer to the first primary question, despite the confounding of the tamoxifen reference arm by the selective crossover to letrozole. The updated results for the MAA are summarized in Table 6. Median follow-up for this analysis is 73 months. <BR>                        The Sequential Treatments Analysis (STA) addresses the second primary question of the study. The primary analysis for the Sequential Treatments Analysis (STA) was from switch (or equivalent time-point in monotherapy arms) + 30 days (STA-S) with a two-sided test applied to each pair-wise comparison at the 2.5% level. Additional analyses were conducted from randomization (STA-R) but these comparisons (added in light of changing medical practice) were under-powered for efficacy. <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="single" width="443" ID="id_c11f33ef-0898-4226-bec7-ded666471e57"><BR>                           <caption ID="id_ad7efac1-9f8f-472e-9969-9f2a04b6ed21">Table 5: Adjuvant Study - Patient and Disease Characteristics (ITT Population)</caption><BR>                           <col width="31.7%"/><BR>                           <col width="14.2%"/><BR>                           <col width="16.3%"/><BR>                           <col width="20.3%"/><BR>                           <col width="17.5%"/><BR>                           <tbody><BR>                              <tr ID="id_739ee15c-9247-4843-8ec8-b81ffc8e8a50"><BR>                                 <td align="left" valign="top" rowspan="2" styleCode="Lrule Toprule Rrule"><BR>                                    <content styleCode="bold">Characteristic</content><BR>                                 </td><BR>                                 <td align="center" valign="top" colspan="2" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold">Primary Core Analysis (PCA)</content><BR>                                 </td><BR>                                 <td align="center" valign="top" colspan="2" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold">Monotherapy Arms Analysis (MAA)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_d50ade5b-a502-4721-83d0-a26dc04a40eb"><BR>                                 <td align="center" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Letrozole</content><BR>                                    <paragraph><BR>                                       <content styleCode="bold"> N = 4003</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">n (%)</content><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Tamoxifen</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">N = 4007</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">n (%)</content><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold"><BR>                                          <content styleCode="bold">Letrozole</content><BR>                                       </content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">N = 2463</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">n (%)</content><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Tamoxifen</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">N = 2459</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">n (%)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_096d9267-5d26-4ac0-939e-e7a43245009f"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Age (median, years)</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">61</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">61</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">61</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">61</td><BR>                              </tr><BR>                              <tr ID="id_6b22e796-f73d-4766-8e47-32af63d7ebe7"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Age range (years)</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">38 to 89</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">39 to 90</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">38 to 88</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">39 to 90</td><BR>                              </tr><BR>                              <tr ID="id_66b74aa0-3783-4c3c-87d5-bfa5146430f9"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Hormone receptor status (%)</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_8b976157-7238-46f8-a3c7-b85077fd5277"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  ER+ and/or PgR+</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">99.7</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">99.7</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">99.7</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">99.7</td><BR>                              </tr><BR>                              <tr ID="id_93c72978-230d-4115-bd39-25286cfccb5d"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Both unknown</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0.3</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0.3</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0.3</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0.3</td><BR>                              </tr><BR>                              <tr ID="id_2ce6185a-b94a-4c7a-af01-4cdca35bec6e"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Nodal status (%)</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_83384524-1bed-4beb-a4d7-b72efa23f1a3"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Node negative</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">52</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">52</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">50</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">52</td><BR>                              </tr><BR>                              <tr ID="id_f347e079-4ce6-4a7e-87ea-a768e866fdf0"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Node positive</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">41</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">41</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">43</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">41</td><BR>                              </tr><BR>                              <tr ID="id_6b42f6a3-d841-41db-82db-26095a5d3f2d"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Nodal status unknown</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">7</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">7</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">7</td><BR>                                 <td align="center" valign="top" styleCode="Lrule Botrule Rrule">7</td><BR>                              </tr><BR>                              <tr ID="id_779811d0-de03-48b5-843b-2f44cab9fe12"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Prior adjuvant chemotherapy (%)</td><BR>                                 <td align="center" valign="top" styleCode="Rrule">24</td><BR>                                 <td align="center" valign="top" styleCode="Rrule">24</td><BR>                                 <td align="center" valign="top" styleCode="Rrule">24</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">24</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="441" ID="id_62c22c5f-6f83-47dc-8b4a-6b37192a40dd"><BR>                           <caption ID="id_d1e87267-6458-4127-90fe-fc68496dd9ad">Table 6: Updated Adjuvant Study Results - Monotherapy Arms Analysis (Median Follow-up 73 Months)</caption><BR>                           <col width="21.5%"/><BR>                           <col width="10.2%"/><BR>                           <col width="12.2%"/><BR>                           <col width="10.2%"/><BR>                           <col width="12.2%"/><BR>                           <col width="9.5%"/><BR>                           <col width="16.8%"/><BR>                           <col width="7.3%"/><BR>                           <tbody><BR>                              <tr ID="id_643506e7-8233-496e-956c-2038dfd949f4"><BR>                                 <td align="left" valign="top" colspan="2" rowspan="2" styleCode="Botrule Toprule Rrule Lrule"/><BR>                                 <td align="center" valign="top" colspan="2" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <paragraph>&#160;<content styleCode="bold">N = 2463</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" colspan="2" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Tamoxifen</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 2459</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Hazard ratio</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_9332ae81-9b9b-456e-beae-507a5e2d2404"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Events</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">(%)</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">5 year</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">rate</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Events</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">(%)</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">5 year</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">rate</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold">(95% CI)</content><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold"><BR>                                       <content styleCode="italics">P</content><BR>                                    </content><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_996ef5da-10cf-4ccf-96eb-a62920d8b020"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Disease-free survival<footnote ID="id-9fa4c6cb-c2a6-4c9e-8f8c-aebe87968deb">Disease-free survival: Interval from randomization to earliest event of invasive loco-regional recurrence, distant metastasis, invasive contralateral breast cancer, or death without a prior event </footnote><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">ITT</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">445 (18.1)</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">87.4</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">500 (20.3)</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">84.7</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.87 (0.76, 0.99)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.03</td><BR>                              </tr><BR>                              <tr ID="id_258a3da1-ab60-46c9-8636-cb423182c3d5"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">Censor</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">445</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">87.4</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">483</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">84.2</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.84 (0.73, 0.95)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_92310967-eb27-4783-bcda-721ca398d8bb"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  0 positive nodes<br/><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">ITT</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">165</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">92.2</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">189</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">90.3</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.88 (0.72, 1.09)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_b50df66d-17b6-493e-99d3-24e1f5d103c1"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  1 to 3   <br/>  positive nodes</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">ITT</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">151</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">85.6</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">163</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">83.0</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.85 (0.68, 1.06)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_d35c9cc0-8bad-421d-9656-a96c9521fa1c"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  &#8805; 4 positive <br/>  nodes</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">ITT</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">123</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">71.2</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">142</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">62.6</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.81 (0.64, 1.03)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_2721a066-89ac-4e99-bf98-7aecda784ece"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Adjuvant <br/>  chemotherapy</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">ITT</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">119</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">86.4</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">150</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">80.6</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.77 (0.60, 0.98)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_0fe38f6d-5495-47f5-913c-a06277340b7f"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  No <br/>  chemotherapy</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">ITT</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">326</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">87.8</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">350</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">86.1</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.91 (0.78, 1.06)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_3d5eb7c0-91cf-4c94-917f-d45dddacb693"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Systemic DFS<footnote ID="id-8d81681d-1a43-44ad-a12d-578e0ee2c76f">Systemic disease-free survival: Interval from randomization to invasive regional recurrence, distant metastasis, or death without a prior cancer event </footnote><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">ITT</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">401</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">88.5</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">446</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">86.6</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.88 (0.77, 1.01)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_922e8499-30ea-4c49-9aeb-4776553a0668"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Time to distant metastasis<footnote ID="id-bedbde34-d7f6-441b-bd39-875875595b62">Time to distant metastasis: Interval from randomization to distant metastasis </footnote><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">ITT</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">257</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">92.4</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">298</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">90.1</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.85 (0.72, 1.00)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_e3271605-2d9f-49b6-a097-a8b8772f6c88"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Adjuvant <br/>  chemotherapy</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">ITT</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">84</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">-</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">109</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">-</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.75 (0.56 to 1.00)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_7974fc0b-fcc0-46b3-87b5-93c0ce1843ac"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  No <br/>  chemotherapy</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">ITT</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">173</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">-</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">189</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">-</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.90 (0.73, 1.11)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_0ce4d6c1-d24a-4bf1-a1a3-6158f2206ac6"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Distant DFS<footnote ID="id-dc308940-fd61-452b-bbfd-4db275b108f2">Distant disease-free survival: Interval from randomization to earlier event of relapse in a distant site or death from any cause </footnote><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">ITT</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">385</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">89.0</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">432</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">87.1</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.87 (0.76, 1.00)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_67f7dcb2-657b-4056-aa95-a2630e600891"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Contralateral breast cancer</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">ITT</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">34</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">99.2</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">44</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">98.6</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.76 (0.49, 1.19)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_751bf543-f7ba-474a-813b-8741ca904269"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Overall survival</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">ITT</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">303</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">91.8</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">343</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">90.9</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.87 (0.75, 1.02)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_cbc29011-3bfb-47be-9382-af4909bd11f0"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">Censor</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">303</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">91.8</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">338</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">90.1</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.82 (0.70, 0.96)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_42305959-34dd-4b3c-ac4b-9e1729e2141e"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  0 positive nodes<br/><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">ITT</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">107</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">95.2</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">121</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">94.8</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.90 (0.69, 1.16)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_92c77cb6-ac96-41d6-9a3c-c11f956243a9"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  1 to 3   <br/>  positive nodes</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">ITT</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">99</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">90.8</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">114</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">90.6</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.81 (0.62, 1.06)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_be51db06-d361-44c7-b64f-8388fdc7fcb0"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  &#8805; 4 positive <br/>  nodes</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">ITT</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">92</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">80.2</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">104</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">73.6</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.86 (0.65, 1.14)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_579cdbb3-cabd-435c-9abb-d58bd75fd58c"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Adjuvant <br/>  chemotherapy</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">ITT</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">76</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">91.5</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">96</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">88.4</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.79 (0.58, 1.06)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_213229ba-9df3-43c5-9279-865f0ae76b87"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  No <br/>  chemotherapy</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">ITT</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">227</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">91.9</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">247</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">91.8</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.91 (0.76, 1.08)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_3d7d1629-920d-4e1f-84fc-0b6663e95afe"><BR>                                 <td align="left" valign="top" colspan="8" styleCode="Lrule Botrule Rrule">Definition of:</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>ITT analysis ignores selective crossover in tamoxifen arms <BR>                        Censored analysis censors follow-up at the date of selective crossover in 632 patients who crossed to letrozole or another aromatase inhibitor after the tamoxifen arms were unblinded in 2005 <BR>                        <BR>                           Figure 1 shows the Kaplan-Meier curves for Disease-Free Survival Monotherapy Analysis <BR>                        <BR>                           Figure 1. Disease-Free Survival (Median follow-up 73 months, ITT Approach)<BR>                        <BR>                        DFS events defined as loco-regional recurrence, distant metastasis, invasive contralateral breast cancer, or death from any cause (i.e., definition excludes second non-breast primary cancers). <BR>                        The medians of overall survival for both arms were not reached for the Monotherapy Arms Analysis (MAA). There was no statistically significant difference in overall survival. The hazard ratio for survival in the letrozole arm compared to the tamoxifen arm was 0.87, with 95% CI (0.75, 1.02) (see <BR>                              Table 6<BR>                           ). There were no significant differences in DFS, OS, SDFS, and Distant DFS from switch in the Sequential Treatments Analysis with respect to either monotherapy (e.g., [Tamoxifen 2 years followed by] letrozole 3 years versus tamoxifen beyond 2 years, DFS HR 0.89; 97.5% CI 0.68, 1.15 and [letrozole 2 years followed by] tamoxifen 3 years versus letrozole beyond 2 years, DFS HR 0.93; 97.5% CI 0.71, 1.22). <BR>                        There were no significant differences in DFS, OS, SDFS, and Distant DFS from randomization in the Sequential Treatments Analyses. <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.2 Extended Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of 24 Months <BR>                     <BR>                        A double-blind, randomized, placebo-controlled trial of letrozole was performed in over 5,100 postmenopausal women with receptor-positive or unknown primary breast cancer who were disease free after 5 years of adjuvant treatment with tamoxifen. <BR>                        The planned duration of treatment for patients in the study was 5 years, but the trial was terminated early because of an interim analysis showing a favorable letrozole effect on time without recurrence or contralateral breast cancer. At the time of unblinding, women had been followed for a median of 28 months, 30% of patients had completed 3 or more years of follow-up and less than 1% of patients had completed 5 years of follow-up. <BR>                        Selected baseline characteristics for the study population are shown in Table 7. <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="single" width="329" ID="id_37e4565b-1634-4f48-8b25-a68fdb51a747"><BR>                           <caption ID="id_7622cb1d-766d-4892-b237-4bd215217d22">Table 7: Selected Study Population Demographics (Modified ITT Population)</caption><BR>                           <col width="50.9%"/><BR>                           <col width="21.9%"/><BR>                           <col width="27.4%"/><BR>                           <tbody><BR>                              <tr ID="id_d2677143-61d3-4866-aaee-20d87c0424eb"><BR>                                 <td align="left" valign="top" styleCode="Botrule Toprule Rrule Lrule"><BR>                                    <content styleCode="bold">Baseline Status</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 2582</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Placebo</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 2586</content><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_47e3fe97-41f7-4b18-91e2-50aed3d00023"><BR>                                 <td align="left" valign="top" colspan="3" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Hormone Receptor Status (%)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_f447b071-2d7b-4681-b5a4-d8dfd50dc277"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  ER+ and/or PgR+</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">98</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">98</td><BR>                              </tr><BR>                              <tr ID="id_c3503eee-6610-4e06-98f7-be1324929cf9"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Both Unknown</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">2</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">2</td><BR>                              </tr><BR>                              <tr ID="id_eee21903-04e0-42a1-8d45-0bf2c8461abd"><BR>                                 <td align="left" valign="top" colspan="3" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Nodal Status (%)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_74c24939-38b5-40d2-8336-796ab6b032d5"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Node Negative</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">50</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">50</td><BR>                              </tr><BR>                              <tr ID="id_c468c9ad-a6f2-4200-8b56-632d1d78513c"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Node Positive</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">46</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">46</td><BR>                              </tr><BR>                              <tr ID="id_297f8be1-300e-4565-b3c4-ee63bd623738"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Nodal Status Unknown</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">4</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">4</td><BR>                              </tr><BR>                              <tr ID="id_13857911-8b9d-48a2-a449-c82b6a4a9305"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Chemotherapy</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Rrule">46</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">46</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR> Table 8 shows the study results. Disease-free survival was measured as the time from randomization to the earliest event of loco-regional or distant recurrence of the primary disease or development of contralateral breast cancer or death. DFS by hormone receptor status, nodal status and adjuvant chemotherapy were similar to the overall results. Data were premature for an analysis of survival. <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="single" width="443" ID="id_fdb09ff5-9d9c-4644-ae9a-d106004e54c1"><BR>                           <caption ID="id_6da01d64-f688-47b9-b8d6-068714eb4a8d">Table 8: Extended Adjuvant Study Results</caption><BR>                           <col width="31.7%"/><BR>                           <col width="16.3%"/><BR>                           <col width="16.3%"/><BR>                           <col width="18.3%"/><BR>                           <col width="17.5%"/><BR>                           <tbody><BR>                              <tr ID="id_eb0c2080-eb1f-4188-ba78-abe3a8c44375"><BR>                                 <td align="left" valign="top" styleCode="Botrule Toprule Rrule Lrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">N = 2582</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Placebo</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 2586</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Hazard Ratio</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">(95% CI)</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold"><BR>                                       <content styleCode="italics">P</content>-Value</content><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_750c8c0f-dafe-4c0d-9821-95255cef2402"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Disease Free Survival (DFS)<footnote ID="id-863391ec-d576-401d-8baa-2b1316faa572">First event of loco-regional recurrence, distant relapse, contralateral breast cancer or death from any cause </footnote> Events</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">122 (4.7%)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">193 (7.5%)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.62 (0.49, 0.78)<footnote ID="id-367b36fa-3b80-42e3-89b8-24246840c322">Analysis stratified by receptor status, nodal status and prior adjuvant chemotherapy (stratification factors as at randomization). <content styleCode="italics">P</content>-value based on stratified logrank test. </footnote><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.00003</td><BR>                              </tr><BR>                              <tr ID="id_e79f0f3b-5019-4a9f-b140-f3259eb79430"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Local Breast Recurrence</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">9</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">22</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_084a8a80-d7c1-46f2-9920-f821c3156bf8"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Local Chest Wall <br/>  Recurrence</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">2</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">8</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_71ed8706-cce3-4d35-b861-3012977e54e1"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Regional Recurrence</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">7</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">4</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_51fc819a-09f3-45fc-8c8c-cf2220580ef1"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Distant Recurrence</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">55</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">92</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.61 (0.44 to  0.84)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.003</td><BR>                              </tr><BR>                              <tr ID="id_c28e142f-87e8-4150-bf11-6bc7fd541361"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Contralateral Breast Cancer</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">19</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">29</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_a4a7a386-5be5-4c92-88be-53b7ffb54549"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Deaths Without Recurrence    or Contralateral Breast    Cancer</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">30</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">38</td><BR>                                 <td align="left" valign="top" styleCode="Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>CI = confidence interval for hazard ratio. Hazard ratio of less than 1.0 indicates difference in favor of letrozole (lesser risk of recurrence); hazard ratio greater than 1.0 indicates difference in favor of placebo (higher risk of recurrence with letrozole). <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.3 Updated Analyses of Extended Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of 60 Months <BR>                     <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="single" width="439" ID="id_b8445533-cf55-4151-9d87-229a61e14d75"><BR>                           <caption ID="id_26361253-e92f-4432-ab81-ee95dc706ea3">Table 9: Update of Extended Adjuvant Study Results</caption><BR>                           <col width="39.0%"/><BR>                           <col width="13.4%"/><BR>                           <col width="15.5%"/><BR>                           <col width="17.3%"/><BR>                           <col width="14.8%"/><BR>                           <tbody><BR>                              <tr ID="id_166f003e-b749-4bba-851d-c0d2176eec2a"><BR>                                 <td align="left" valign="top" styleCode="Botrule Toprule Rrule Lrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">N = 2582</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">(%)</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Placebo</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">N = 2586</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">(%)</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Hazard Ratio</content><BR>                                       <content styleCode="bold"><BR>                                          <footnote ID="id-b9597323-667d-4241-9720-01405ff77539">Adjusted by receptor status, nodal status and prior chemotherapy </footnote><BR>                                       </content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">(95% CI)</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold"><BR>                                       <content styleCode="italics">P</content>-Value<footnote ID="id-757e8619-aeb1-444f-ae71-25a571874f64">Stratified logrank test, stratified by receptor status, nodal status and prior chemotherapy </footnote><BR>                                    </content><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_37456563-00ce-41cd-801e-9db939ba8974"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Disease Free Survival (DFS) events</content><BR>                                    <footnote ID="id-d11c406d-cc8a-4139-b280-ee4ff59159f9">DFS events defined as earliest of loco-regional recurrence, distant metastasis, contralateral breast cancer or death from any cause, and ignoring switches to letrozole in 60% of the placebo arm.</footnote><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">344 (13.3)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">402 (15.5)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.89 (0.77, 1.03)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.12</td><BR>                              </tr><BR>                              <tr ID="id_34a7e964-5d5a-465f-acac-bcb60a9d7dd0"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Breast Cancer Recurrence</content><BR>                                    </paragraph>(Protocol definition of DFS events<footnote ID="id-feebbdb5-5c06-4bcd-ae40-29fe012d171e">Protocol definition does not include deaths from any cause </footnote>) </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">209</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">286</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.75 (0.63, 0.89)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.001</td><BR>                              </tr><BR>                              <tr ID="id_67dae147-99b0-4b9c-af35-baf822bdfb7b"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Local Breast Recurrence</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">15</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">44</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_5df2a15e-7b13-482c-984e-7c9238033a8c"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Local Chest Wall <br/>  Recurrence</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">6</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">14</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_cb740f50-485d-4095-8a9a-02b3cf36dcae"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Regional Recurrence</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">10</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">8</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_47ae0d4e-5595-4ee6-9c97-6ef5c5d5a07d"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_6020e907-0185-48db-af0d-32e511c2263f"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Distant Recurrence</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">140</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">167</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_c094e07b-d6f4-4a1d-91e7-5629583e54da"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Distant Recurrence (first or  <br/>  subsequent events)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">142</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">169</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.88 (0.70, 1.10)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.246</td><BR>                              </tr><BR>                              <tr ID="id_c66d7175-f2e7-4ac1-ac50-2731c2f75158"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Contralateral Breast Cancer</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">37</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">53</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_dfdb8762-158e-490c-aeea-3ff0df35b654"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Deaths Without Recurrence or  <br/>  Contralateral Breast Cancer</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">135</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">116</td><BR>                                 <td align="left" valign="top" styleCode="Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Updated analyses were conducted at a median follow-up of 62 months. In the letrozole arm, 71% of the patients were treated for a least 3 years and 58% of patients completed at least 4.5 years of extended adjuvant treatment. After the unblinding of the study at a median follow-up of 28 months, approximately 60% of the selected patients in the placebo arm opted to switch to letrozole. <BR>                        In this updated analysis shown in Table 9, letrozole significantly reduced the risk of breast cancer recurrence or contralateral breast cancer compared with placebo (HR 0.75; 95% CI 0.63, 0.89; P = 0.001). However, in the updated DFS analysis (interval between randomization and earliest event of loco-regional recurrence, distant metastasis, contralateral breast cancer, or death from any cause) the treatment difference was heavily diluted by 60% of the patients in the placebo arm switching to letrozole and accounting for 64% of the total placebo patient- years of follow-up. Ignoring these switches, the risk of DFS event was reduced by a non-significant 11% (HR 0.89; 95% CI 0.77, 1.03). There was no significant difference in distant disease-free survival or overall survival. <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.4 First-Line Treatment of Advanced Breast Cancer <BR>                     <BR>                        A randomized, double-blind, multinational trial compared letrozole 2.5 mg with tamoxifen 20 mg in 916 postmenopausal patients with locally advanced (Stage IIIB or loco-regional recurrence not amenable to treatment with surgery or radiation) or metastatic breast cancer. Time to progression (TTP) was the primary endpoint of the trial. Selected baseline characteristics for this study are shown in Table 10. <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="single" width="443" ID="id_850b9b5a-ebf7-42d9-898d-0dd37c8c1943"><BR>                           <caption ID="id_9e598144-4ae4-4ad6-9c22-31eac263574d">Table 10: Selected Study Population Demographics</caption><BR>                           <col width="41.9%"/><BR>                           <col width="30.5%"/><BR>                           <col width="27.6%"/><BR>                           <tbody><BR>                              <tr ID="id_c392f5e8-e37d-4bc1-aa35-2ab183657c36"><BR>                                 <td align="left" valign="top" styleCode="Botrule Toprule Rrule Lrule"><BR>                                    <content styleCode="bold">Baseline Status</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 458</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Tamoxifen</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 458</content><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_cc020844-09ff-4d63-b5ff-7d4ae8f470c3"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Stage of Disease</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_c2b81285-dff8-417a-a90e-31375b9d09df"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  IIIB</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">6%</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">7%</td><BR>                              </tr><BR>                              <tr ID="id_27eab40d-af76-4ef2-b9d7-068ea5510cd3"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  IV</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">93%</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">92%</td><BR>                              </tr><BR>                              <tr ID="id_2269b6f0-f503-4495-8bdd-23f70c0e643a"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Receptor Status</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_bb3fbb02-c0e1-4917-b1f3-a1c1db6e2cf1"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  ER and PgR Positive</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">38%</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">41%</td><BR>                              </tr><BR>                              <tr ID="id_d5b95250-47f7-4603-b747-489e000979ac"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  ER or PgR Positive </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">26%</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">26%</td><BR>                              </tr><BR>                              <tr ID="id_43e99ea8-a128-4400-bb16-b2ed6b1e99af"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Both Unknown</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">34%</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">33%</td><BR>                              </tr><BR>                              <tr ID="id_9d063a06-d9bb-49d2-83c8-bd99f7afae4d"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  ER<sup>-</sup> or PgR<sup>-</sup>/Other Unknown</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">&lt; 1%</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0</td><BR>                              </tr><BR>                              <tr ID="id_4e151f6a-5d15-4a09-abb2-13abdddd4748"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Previous Antiestrogen Therapy</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_18c4822a-7f31-41e8-a6a7-ca34fd0eabe3"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Adjuvant</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">19%</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">18%</td><BR>                              </tr><BR>                              <tr ID="id_40a482a7-ab24-4a93-ac63-f8448469ac7b"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  None</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">81%</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">82%</td><BR>                              </tr><BR>                              <tr ID="id_1be8e74c-912c-4e35-b807-66eae5ac6c28"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Dominant Site of Disease</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_da946675-efcd-4227-9f8a-5490c594eebe"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Soft Tissue</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">25%</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">25%</td><BR>                              </tr><BR>                              <tr ID="id_14c5194d-8fc5-4f07-887d-b032b13f407b"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Bone</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">32%</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">29%</td><BR>                              </tr><BR>                              <tr ID="id_94fa3837-39f3-46d7-ae7c-0268a501938a"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Viscera</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">43%</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">46%</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR> Letrozole was superior to tamoxifen in TTP and rate of objective tumor response (see <BR>                              Table 11<BR>                           ). <BR>                        <BR>                           Table 11 summarizes the results of the trial, with a total median follow-up of approximately 32 months. <BR>                        (All analyses are unadjusted and use 2-sided P-values.) <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="single" width="437" ID="id_b3dca160-ca32-478e-9313-832df630f3f6"><BR>                           <caption ID="id_dca6bdd1-3698-4f9c-b7b8-14c2b83af716">Table 11: Results of First-Line Treatment of Advanced Breast Cancer</caption><BR>                           <col width="40.4%"/><BR>                           <col width="18.5%"/><BR>                           <col width="17.1%"/><BR>                           <col width="24.1%"/><BR>                           <tbody><BR>                              <tr ID="id_9483074b-c9f2-4190-b03d-a0d9a0f94620"><BR>                                 <td align="left" valign="top" styleCode="Botrule Toprule Rrule Lrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">2.5 mg</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">N = 453</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Tamoxifen</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">20 mg</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 454</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Hazard or Odds Ratio (95% CI) </content><BR>                                    </paragraph><BR>                                    <content styleCode="bold"><BR>                                       <content styleCode="italics">P</content>-Value (2-Sided)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_48c06be7-c134-4a4d-bc72-16f83009aaba"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Median Time to Progression</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">9.4 months</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">6.0 months</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph>0.72 (0.62, 0.83)<footnote ID="id-a2b111bd-936d-4adb-8b61-01372732df40">Hazard ratio </footnote><BR>                                    </paragraph><BR>                                    <content styleCode="italics">P</content> &lt; 0.0001</td><BR>                              </tr><BR>                              <tr ID="id_d2279c17-39e1-4313-ba8d-4679359735e3"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Objective Response Rate</content><BR>                                    </paragraph>&#160;  (CR + PR)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">145 (32%)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">95 (21%)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph>1.77 (1.31, 2.39)<footnote ID="id-8a323f59-67e6-4bfc-bfbd-faeb91535c19">Odds ratio </footnote><BR>                                    </paragraph><BR>                                    <content styleCode="italics">P</content> = 0.0002</td><BR>                              </tr><BR>                              <tr ID="id_907e9ae6-b524-4ee6-93f3-7164f32dcb2b"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  (CR)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">42 (9%)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">15 (3%)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph>2.99 (1.63, 5.47)<footnoteRef IDREF="id-8a323f59-67e6-4bfc-bfbd-faeb91535c19"/><BR>                                    </paragraph><BR>                                    <content styleCode="italics">P</content> = 0.0004</td><BR>                              </tr><BR>                              <tr ID="id_cc65ccfd-6127-4050-a9ef-2672fb864ef8"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Duration of Objective Response</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_75f2e369-e46c-4ba5-a449-85554eb9f03b"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Median</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph>18 months</paragraph>(N = 145)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph>16 months</paragraph>(N = 95)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_dd7e9351-2914-4c41-92f3-abc09a122c8e"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Overall Survival</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Rrule"><BR>                                    <paragraph>35 months</paragraph>(N = 458)</td><BR>                                 <td align="left" valign="top" styleCode="Rrule"><BR>                                    <paragraph>32 months</paragraph>(N = 458)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <content styleCode="italics">P</content> = 0.5136<footnote ID="id-68c7e0a6-7903-4cf3-98b5-1b855fa1de13">Overall logrank test </footnote><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR>                           Figure 2 shows the Kaplan-Meier curves for TTP. <BR>                        <BR>                           Figure 2. Kaplan-Meier Estimates of Time to Progression (Tamoxifen Study)<BR>                        <BR>                        <BR>                           Table 12 shows results in the subgroup of women who had received prior antiestrogen adjuvant therapy, Table 13, results by disease site and Table 14, the results by receptor status. <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="single" width="443" ID="id_f1540f4c-b8aa-4cb3-9433-d1771f205c4f"><BR>                           <caption ID="id_d6f825f8-831e-42a1-9e8a-2cf821c8e392">Table 12: Efficacy in Patients Who Received Prior Antiestrogen Therapy</caption><BR>                           <col width="47.9%"/><BR>                           <col width="26.4%"/><BR>                           <col width="25.6%"/><BR>                           <tbody><BR>                              <tr ID="id_43ba3049-f71c-4468-94c0-9756d47420d9"><BR>                                 <td align="left" valign="top" styleCode="Botrule Toprule Rrule Lrule"><BR>                                    <content styleCode="bold">Variable</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">2.5 mg</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 84</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Tamoxifen</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">20 mg</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 83</content><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_49bd0452-5bfb-47f6-9532-90a543d37ae0"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Median Time to Progression</content> (95% CI)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">8.9 months (6.2, 12.5)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">5.9 months (3.2, 6.2)</td><BR>                              </tr><BR>                              <tr ID="id_4674b4f7-dccd-4292-962c-2ecf04f8a4bc"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Hazard Ratio for TTP (95% CI)</td><BR>                                 <td align="center" valign="top" colspan="2" styleCode="Botrule Rrule">0.60 (0.43, 0.84)</td><BR>                              </tr><BR>                              <tr ID="id_bfba2cdf-ca6c-4840-a064-497810e5802e"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Objective Response Rate</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_e8bf5164-f981-47c4-a8c5-ec9ee68b146b"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  (CR + PR)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">22 (26%)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">7 (8%)</td><BR>                              </tr><BR>                              <tr ID="id_c99f9387-26e4-4bd9-bb59-3eb974a4aab3"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Odds Ratio for Response  (95% CI)<br/><BR>                                 </td><BR>                                 <td align="center" valign="top" colspan="2" styleCode="Botrule Rrule">3.85 (1.50, 9.60)</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR> Hazard ratio less than 1 or odds ratio greater than 1 favors letrozole; hazard ratio greater than 1 or odds ratio less than 1 favors tamoxifen. <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="single" width="443" ID="id_bdc90763-ac65-4cd7-85a2-c53a1f93aefe"><BR>                           <caption ID="id_3ba3def0-f3f1-4a78-a992-00834acb3709">Table 13: Efficacy by Disease Site</caption><BR>                           <col width="33.3%"/><BR>                           <col width="33.3%"/><BR>                           <col width="33.3%"/><BR>                           <tbody><BR>                              <tr ID="id_c5ccc391-c11f-4e57-a385-a5932a167143"><BR>                                 <td align="left" valign="top" styleCode="Botrule Toprule Rrule Lrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">2.5 mg</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Tamoxifen</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">20 mg</content><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_1feae1d6-4a0a-4696-a98b-861fd325f22c"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Dominant Disease Site</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_22c6dc90-96d7-4812-ad85-5ff42470d31b"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Soft Tissue:</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">N = 113</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">N = 115</td><BR>                              </tr><BR>                              <tr ID="id_f8a814b5-c8a5-4ecb-9cb7-8b13ace9f783"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Median TTP</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">12.1 months</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">6.4 months</td><BR>                              </tr><BR>                              <tr ID="id_dca8b39a-99e2-45ef-96ed-c7e13e2606b1"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Objective Response Rate</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">50%</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">34%</td><BR>                              </tr><BR>                              <tr ID="id_e6d30183-ff7f-4ee3-acf0-eda03e9a9547"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Bone:</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">N = 145</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">N = 131</td><BR>                              </tr><BR>                              <tr ID="id_a0a0e13c-f849-46ba-9dc1-1ae04c15abdf"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Median TTP</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">9.5 months</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">6.3 months</td><BR>                              </tr><BR>                              <tr ID="id_cdbc3682-bd26-45c4-9897-8bbbe8ba4ba0"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Objective Response Rate</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">23%</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">15%</td><BR>                              </tr><BR>                              <tr ID="id_bcfc1f9f-1683-4d3d-8bd1-0fabb7fb727f"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Viscera:</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">N = 195</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">N = 208</td><BR>                              </tr><BR>                              <tr ID="id_3362924f-0126-403d-9c26-4ab3fc6e5155"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Median TTP</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">8.3 months</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">4.6 months</td><BR>                              </tr><BR>                              <tr ID="id_d97849e9-a7e3-4de3-893c-0eca36ebe1d7"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Objective Response Rate</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">28%</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">17%</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="single" width="443" ID="id_e22b93b1-bf15-4c69-aa9d-2f1f7c6df0c3"><BR>                           <caption ID="id_f7943abc-64a8-4a5f-8bc7-a6919da07fe7">Table 14: Efficacy by Receptor Status</caption><BR>                           <col width="45.9%"/><BR>                           <col width="28.4%"/><BR>                           <col width="25.6%"/><BR>                           <tbody><BR>                              <tr ID="id_142ac9d6-6e52-41b6-be17-06b91540bb8c"><BR>                                 <td align="left" valign="top" styleCode="Botrule Toprule Rrule Lrule"><BR>                                    <content styleCode="bold">Variable</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">2.5 mg</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Tamoxifen </content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">20 mg</content><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_c6e9d710-b1ef-49dd-89fd-f14d3270eae8"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Receptor Positive</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">N = 294</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">N = 305</td><BR>                              </tr><BR>                              <tr ID="id_084c1b5f-6628-45ab-8552-cab9049b9a04"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Median Time to Progression (95% CI)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">9.4 months (8.9, 11.8)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">6.0 months (5.1, 8.5)</td><BR>                              </tr><BR>                              <tr ID="id_3852ffec-b09e-47f8-bbce-3251cf37ff73"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Hazard Ratio for TTP (95% CI)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.69 (0.58, 0.83)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_3e9d2e45-bfc1-4429-b53f-e2219e5c2722"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Objective Response Rate (CR+PR)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">97 (33%)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">66 (22%)</td><BR>                              </tr><BR>                              <tr ID="id_ae91ab51-b6ac-41bd-9512-8f97ed833c58"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Odds Ratio for Response 95% CI)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">1.78 (1.20, 2.60)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_c7da4677-c99c-49ce-956d-fa72c2cbad73"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Receptor Unknown</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">N = 159</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">N = 149</td><BR>                              </tr><BR>                              <tr ID="id_59f5c601-4dad-422d-beab-793bea289ce2"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Median Time to Progression (95% CI)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">9.2 months (6.1, 12.3)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">6.0 months (4.1, 6.4)</td><BR>                              </tr><BR>                              <tr ID="id_1c1e4d36-4153-49bb-b2c7-646f000b9969"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Hazard Ratio for TTP (95% CI)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">0.77 (0.60, 0.99)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_27398125-bfa7-4874-ac48-308882463979"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Objective Response Rate (CR+PR)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">48 (30%)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">29 (20%)</td><BR>                              </tr><BR>                              <tr ID="id_11d73b41-c039-447a-9740-35eb5639ebe2"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Odds Ratio for Response (95% CI)</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">1.79 (1.10, 3.00)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR> Hazard ratio less than 1 or odds ratio greater than 1 favors letrozole; hazard ratio greater than 1 or odds ratio less than 1 favors tamoxifen. <BR>                        <BR>                           Figure 3 shows the Kaplan-Meier curves for survival. <BR>                        <BR>                           Figure 3. Survival by Randomized Treatment Arm<BR>                        <BR>                        <BR>                           Legend: Randomized letrozole: n = 458, events 57%, median overall survival 35 months (95% CI 32 to 38 months) <BR>                        Randomized tamoxifen: n = 458, events 57%, median overall survival 32 months (95% CI 28 to 37 months) <BR>                        Overall logrank P = 0.5136 (i.e., there was no significant difference between treatment arms in overall survival). <BR>                        The median overall survival was 35 months for the letrozole group and 32 months for the tamoxifen group, with a P-value 0.5136. Study design allowed patients to cross over upon progression to the other therapy. Approximately 50% of patients crossed over to the opposite treatment arm and almost all patients who crossed over had done so by 36 months. The median time to crossover was 17 months (letrozole to tamoxifen) and 13 months (tamoxifen to letrozole). In patients who did not cross over to the opposite treatment arm, median survival was 35 months with letrozole (n = 219, 95% CI 29 to 43 months) vs 20 months with tamoxifen (n = 229, 95% CI 16 to 26 months). <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.5 Second-Line Treatment of Advanced Breast Cancer <BR>                     <BR>                        Letrozole was initially studied at doses of 0.1 mg to 5.0 mg daily in six non-comparative Phase I/II trials in 181 postmenopausal estrogen/progesterone receptor positive or unknown advanced breast cancer patients previously treated with at least antiestrogen therapy. Patients had received other hormonal therapies and also may have received cytotoxic therapy. Eight (20%) of forty patients treated with letrozole 2.5 mg daily in Phase I/II trials achieved an objective tumor response (complete or partial response). <BR>                        Two large randomized, controlled, multinational (predominantly European) trials were conducted in patients with advanced breast cancer who had progressed despite antiestrogen therapy. Patients were randomized to letrozole 0.5 mg daily, letrozole 2.5 mg daily, or a comparator (megestrol acetate 160 mg daily in one study; and aminoglutethimide 250 mg b.i.d. with corticosteroid supplementation in the other study). In each study over 60% of the patients had received therapeutic antiestrogens, and about one-fifth of these patients had had an objective response. The megestrol acetate controlled study was double-blind; the other study was open label. Selected baseline characteristics for each study are shown in Table 15. <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="single" width="443" ID="id_3f91252e-b4d0-4c91-b27c-be7276b133eb"><BR>                           <caption ID="id_c3dee0ef-6aad-49fe-8dc5-34d558c03f8c">Table 15: Selected Study Population Demographics</caption><BR>                           <col width="33.3%"/><BR>                           <col width="33.3%"/><BR>                           <col width="33.3%"/><BR>                           <tbody><BR>                              <tr ID="id_eb7932a2-7b1d-4bb8-904e-e24067e74a04"><BR>                                 <td align="left" valign="top" styleCode="Botrule Toprule Rrule Lrule"><BR>                                    <content styleCode="bold">Parameter</content><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold">megestrol acetate study</content><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold">aminoglutethimide study</content><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_cff0f597-06ce-40a6-82aa-a5831c8884df"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">No. of Participants</content><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">552</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">557</td><BR>                              </tr><BR>                              <tr ID="id_8595787a-550a-4a64-a0cc-4f9066360d7e"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Receptor Status</content><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_280630b9-d871-4328-8131-8f5bad8ab317"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  ER/PR Positive</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">57%</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">56%</td><BR>                              </tr><BR>                              <tr ID="id_dfdfe94e-4e9c-4c4a-b2fc-048d7d53c507"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  ER/PR Unknown</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">43%</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">44%</td><BR>                              </tr><BR>                              <tr ID="id_6ac78585-f6f9-4e7a-8fda-eda0af10ec68"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Previous Therapy</content><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_3bb77499-688d-4968-a017-53a55bf528fb"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Adjuvant Only</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">33%</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">38%</td><BR>                              </tr><BR>                              <tr ID="id_fac582bc-0b75-4606-8579-389de71d99bb"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Therapeutic +/- Adj.</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">66%</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">62%</td><BR>                              </tr><BR>                              <tr ID="id_10ffef5d-c352-420f-8aaf-636f5e34f7fa"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Sites of Disease</content><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_3a75efd1-f557-4a1e-94d5-4846c1474bca"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Soft Tissue</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">56%</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">50%</td><BR>                              </tr><BR>                              <tr ID="id_debe118a-295e-4dc2-b496-b81bf6d9bdc0"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Bone</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">50%</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">55%</td><BR>                              </tr><BR>                              <tr ID="id_d42e0547-69ae-46cd-8c81-766426d30397"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">  Viscera</td><BR>                                 <td align="center" valign="top" styleCode="Rrule">40%</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">44%</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR> Confirmed objective tumor response (complete response plus partial response) was the primary endpoint of the trials. Responses were measured according to the Union Internationale Contre le Cancer (UICC) criteria and verified by independent, blinded review. All responses were confirmed by a second evaluation 4 to 12 weeks after the documentation of the initial response.  <BR>                        <BR>                           Table 16 shows the results for the first trial, with a minimum follow-up of 15 months, that compared letrozole 0.5 mg, letrozole 2.5 mg, and megestrol acetate 160 mg daily. (All analyses are unadjusted.) <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="single" width="455" ID="id_b86f9ac2-6741-4df0-93d1-ebb90f01ff42"><BR>                           <caption ID="id_e71c9eba-d6cf-49de-9f06-9e12951d07b1">Table 16: Megestrol Acetate Study Results</caption><BR>                           <col width="26.9%"/><BR>                           <col width="21.8%"/><BR>                           <col width="24.3%"/><BR>                           <col width="27.1%"/><BR>                           <tbody><BR>                              <tr ID="id_9df77c04-82cd-470e-b7d8-e2bef7d73b56"><BR>                                 <td align="left" valign="top" styleCode="Botrule Toprule Rrule Lrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">0.5 mg</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 188</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">2.5 mg</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 174</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Megestrol acetate</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 190</content><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_c8064247-c6f7-4841-8491-1e7488d1d753"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Objective Response (CR + PR)</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">22 (11.7%)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">41 (23.6%)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">31 (16.3%)</td><BR>                              </tr><BR>                              <tr ID="id_fbe01a85-9c0d-45d1-bcfd-90dad2831b9c"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Median Duration of Response</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">552 days</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">(Not reached)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">561 days</td><BR>                              </tr><BR>                              <tr ID="id_8e20146b-048a-45d8-9b2c-c7f9cb7151ba"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Median Time to Progression</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">154 days</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">170 days</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">168 days</td><BR>                              </tr><BR>                              <tr ID="id_7d6e0136-9ebd-492d-9d7e-b0128e6c0f9c"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Median Survival</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">633 days</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">730 days</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">659 days</td><BR>                              </tr><BR>                              <tr ID="id_78f67e1f-6e2a-4fe6-847e-dc07349ed60e"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Odds Ratio for Response</content><BR>                                 </td><BR>                                 <td align="left" valign="top" colspan="2" styleCode="Botrule Rrule">letrozole 2.5: letrozole 0.5 = 2.33 (95% CI: 1.32, 4.17); <content styleCode="italics">P</content> = 0.004<footnote ID="id-dcba7483-2045-4d56-8c31-162f785e09f1">two-sided <content styleCode="italics">P</content>-value </footnote><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">letrozole 2.5: megestrol = 1.58 (95% CI: 0.94, 2.66); <content styleCode="italics">P</content> = 0.08<footnoteRef IDREF="id-dcba7483-2045-4d56-8c31-162f785e09f1"/><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_3561b560-61ea-401e-8bd9-c674203e5f54"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Relative Risk of Progression</content><BR>                                 </td><BR>                                 <td align="left" valign="top" colspan="2" styleCode="Rrule">letrozole 2.5: letrozole 0.5 = 0.81 (95% CI: 0.63, 1.03); <content styleCode="italics">P</content> = 0.09<footnoteRef IDREF="id-dcba7483-2045-4d56-8c31-162f785e09f1"/><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">letrozole 2.5: megestrol = 0.77 (95% CI: 0.60, 0.98); <content styleCode="italics">P</content> = 0.03<footnoteRef IDREF="id-dcba7483-2045-4d56-8c31-162f785e09f1"/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>The Kaplan-Meier curves for progression for the megestrol acetate study are shown in Figure 4. <BR>                        <BR>                           Figure 4. Kaplan-Meier Estimates of Time to Progression (Megestrol Acetate Study)<BR>                        <BR>                        The results for the study comparing letrozole to aminoglutethimide, with a minimum follow-up of 9 months, are shown in Table 17. (Unadjusted analyses are used.) <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="single" width="455" ID="id_d4030dc0-d9ca-45d9-8d8a-2a61d734fc0d"><BR>                           <caption ID="id_8724676c-e299-4853-873c-889ae219804e">Table 17: Aminoglutethimide Study Results</caption><BR>                           <col width="26.9%"/><BR>                           <col width="21.8%"/><BR>                           <col width="24.3%"/><BR>                           <col width="27.1%"/><BR>                           <tbody><BR>                              <tr ID="id_d45b1bd6-803c-4ce8-8a47-d2d5069d3aa7"><BR>                                 <td align="left" valign="top" styleCode="Botrule Toprule Rrule Lrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">0.5 mg</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 193</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">2.5 mg</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 185</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Aminoglutethimide</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 179</content><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_64b9ed1a-6872-4f23-8de0-eea581d53f32"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Objective Response (CR + PR)</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">34 (17.6%)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">34 (18.4%)</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">22 (12.3%)</td><BR>                              </tr><BR>                              <tr ID="id_c6be9d5f-db6a-4b92-b5a1-8ae325f3daef"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Median Duration of Response</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">619 days</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">706 days</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">450 days</td><BR>                              </tr><BR>                              <tr ID="id_2f3e20ae-cc11-468f-8b33-2893160f455f"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Median Time to Progression</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">103 days</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">123 days</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">112 days</td><BR>                              </tr><BR>                              <tr ID="id_9b216a42-6449-40fc-b302-911ceb9da81d"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Median Survival</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">636 days</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">792 days</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">592 days</td><BR>                              </tr><BR>                              <tr ID="id_8e57bbbf-1e70-43ad-8598-95c47a8a3643"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Odds Ratio for Response</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">letrozole 2.5: letrozole 0.5 = 1.05 (95% CI: 0.62, 1.79); <content styleCode="italics">P</content> = 0.85<footnote ID="id-ea0e6777-ee8a-41ec-87a4-cb237c17e33b">two-sided <content styleCode="italics">P</content>-value </footnote><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">letrozole 2.5: aminoglutethimide = 1.61 (95% CI: 0.90, 2.87); <content styleCode="italics">P</content> = 0.11<footnoteRef IDREF="id-ea0e6777-ee8a-41ec-87a4-cb237c17e33b"/><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_301dae44-062c-4c99-8416-00f4cceca593"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Relative Risk of Progression</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Rrule">letrozole 2.5: letrozole 0.5 = 0.86 (95% CI: 0.68, 1.11); <content styleCode="italics">P</content> = 0.25<footnoteRef IDREF="id-ea0e6777-ee8a-41ec-87a4-cb237c17e33b"/><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">letrozole 2.5: aminoglutethimide = 0.74 (95% CI: 0.57, 0.94); <content styleCode="italics">P</content> = 0.02<footnoteRef IDREF="id-ea0e6777-ee8a-41ec-87a4-cb237c17e33b"/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>The Kaplan-Meier curves for progression for the aminoglutethimide study is shown in Figure 5. <BR>                        <BR>                           Figure 5. Kaplan-Meier Estimates of Time to Progression (Aminoglutethimide Study)<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     Figure 1. Disease-Free Survival (Median follow-up 73 months, ITT Approach)<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     Figure 2 Kaplan-Meier Esitmates of Time to Progression (Tamoxifen Study)<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     Figure 3 Survival by Randomized Treatment Arm<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     Figure 4. Kaplan-Meier Estimates of Time to Progression (Megestrol Acetate Study)<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     Figure 5 Kaplan-Meier Estimates of Time to Progression (Aminoglutethimide Study)<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>